Jefferies Financial Group Inc. Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Jefferies Financial Group Inc.

  • $13.5 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
BUY
$22.82 - $35.32 $823,802 - $1.28 Million
36,100 Added 259.71%
50,000 $1.22 Million
Q4 2022

Sep 21, 2023
BUY
$25.35 - $31.96 $352,365 - $444,244
13,900 New
13,900 $438,000
Q4 2022

Feb 14, 2023
BUY
$25.35 - $31.96 $352,365 - $444,244
13,900 New
13,900 $438,000

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email